Illumina Inc. (NASDAQ:ILMN) – Investment analysts at First Analysis reduced their FY2016 earnings estimates for shares of Illumina in a research report issued to clients and investors on Tuesday. First Analysis analyst T. Marshbanks now expects that the brokerage will post earnings of $3.34 per share for the year, down from their prior estimate of $3.51. First Analysis also issued estimates for Illumina’s Q4 2016 earnings at $0.92 EPS, Q1 2017 earnings at $0.79 EPS and FY2017 earnings at $3.58 EPS.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The firm had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. During the same quarter in the previous year, the company posted $0.80 EPS. The business’s revenue was up 11.3% on a year-over-year basis.

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

ILMN has been the topic of a number of other research reports. Citigroup Inc. raised their price target on Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, September 12th. Canaccord Genuity set a $136.00 price target on Illumina and gave the company a “hold” rating in a research report on Friday, October 7th. Vetr upgraded Illumina from a “sell” rating to a “buy” rating and set a $198.61 price target on the stock in a research report on Monday, October 3rd. CL King downgraded Illumina from a “buy” rating to a “neutral” rating in a research report on Monday, August 22nd. Finally, Morgan Stanley downgraded Illumina from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $130.00 to $110.00 in a research report on Tuesday, July 5th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Illumina presently has an average rating of “Hold” and an average price target of $157.50.

Illumina (NASDAQ:ILMN) traded up 0.2870% during midday trading on Thursday, hitting $136.5708. The company’s stock had a trading volume of 1,141,348 shares. The stock has a 50 day moving average of $172.97 and a 200 day moving average of $156.29. Illumina has a 52-week low of $127.10 and a 52-week high of $196.47. The company has a market cap of $20.02 billion, a PE ratio of 46.7708 and a beta of 0.47.

In other news, Director Robert S. Epstein sold 300 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $174.29, for a total transaction of $52,287.00. Following the completion of the sale, the director now owns 6,924 shares of the company’s stock, valued at approximately $1,206,783.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction on Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the sale, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $3,146,103.40. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of ILMN. Checchi Capital Advisers LLC increased its stake in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the last quarter. Cleararc Capital Inc. increased its stake in shares of Illumina by 0.7% in the first quarter. Cleararc Capital Inc. now owns 3,344 shares of the life sciences company’s stock worth $542,000 after buying an additional 23 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of Illumina by 1.1% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 3,698 shares of the life sciences company’s stock worth $467,000 after buying an additional 39 shares during the last quarter. Nippon Life Insurance Co. increased its stake in shares of Illumina by 0.5% in the second quarter. Nippon Life Insurance Co. now owns 7,877 shares of the life sciences company’s stock worth $1,106,000 after buying an additional 40 shares during the last quarter. Finally, Regent Investment Management LLC increased its stake in shares of Illumina by 1.8% in the second quarter. Regent Investment Management LLC now owns 4,250 shares of the life sciences company’s stock worth $597,000 after buying an additional 75 shares during the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.